retatrutide clinical trial data Phase 3: TRIUMPH Program Results 2026 Retatrutide for weight loss: Study

M Rizzo is full-time Professor of Internal Medicine at University of Palermo, Italy and currently Medical Director, Novo Nordisk Eastern Europe

ABSTRACT Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering medications with salient benefits for body weight and cardiovascular events

Remove the needle and safely dispose of it in a sharps container

Treatment discontinuation due to adverse events reached 7.7% in the 12 mg TRIUMPH-2 group and 13.5% in the 12 mg TRIUMPH-3 group

[5] They can also cause kidney strain from dehydration, and gallbladder or biliary issues, with rare cases of pancreatitis showing up too

Changes in taste and sensory appeal Consumer taste preferences are also changing, influenced by GLP-1 activity in taste receptors